SK287838B6 - Method for production of coating and excipient agent for oral or dermal dosage forms - Google Patents

Method for production of coating and excipient agent for oral or dermal dosage forms Download PDF

Info

Publication number: SK287838B6
Authority: SK; Slovakia
Prior art keywords: coating; water; copolymer; polymer; tablets
Prior art date: 1998-07-23

Application number

SK79-2001A

Other languages

English (en)

Slovak (sk)

Other versions

SK792001A3 (en

Inventor

Hans-Ulrich Petereit

Christian Meier

Erna Roth

Original Assignee

Evonik Rohm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-23

Filing date

1999-07-02

Publication date

2011-12-05

1999-07-02 Application filed by Evonik Rohm Gmbh filed Critical Evonik Rohm Gmbh

2002-01-07 Publication of SK792001A3 publication Critical patent/SK792001A3/sk

2011-12-05 Publication of SK287838B6 publication Critical patent/SK287838B6/sk

Links

238000000576 coating method Methods 0.000 title claims abstract description 56
239000011248 coating agent Substances 0.000 title claims abstract description 50
238000004519 manufacturing process Methods 0.000 title claims abstract description 18
239000003795 chemical substances by application Substances 0.000 title claims abstract description 14
239000002552 dosage form Substances 0.000 title claims abstract description 14
230000002500 effect on skin Effects 0.000 title claims abstract description 6
239000000546 pharmaceutical excipient Substances 0.000 title abstract description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 62
229920001577 copolymer Polymers 0.000 claims abstract description 40
239000000843 powder Substances 0.000 claims abstract description 25
239000003995 emulsifying agent Substances 0.000 claims abstract description 24
239000002245 particle Substances 0.000 claims abstract description 23
238000005507 spraying Methods 0.000 claims abstract description 15
238000000034 method Methods 0.000 claims abstract description 14
239000000178 monomer Substances 0.000 claims abstract description 10
239000000654 additive Substances 0.000 claims abstract description 9
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims abstract description 6
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims abstract description 5
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims abstract description 5
238000005266 casting Methods 0.000 claims abstract description 5
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 4
238000002844 melting Methods 0.000 claims abstract description 4
230000008018 melting Effects 0.000 claims abstract description 4
239000000203 mixture Substances 0.000 claims description 50
239000011230 binding agent Substances 0.000 claims description 25
239000004014 plasticizer Substances 0.000 claims description 19
239000004480 active ingredient Substances 0.000 claims description 11
239000000049 pigment Substances 0.000 claims description 11
230000008569 process Effects 0.000 claims description 6
238000010030 laminating Methods 0.000 claims description 5
239000008199 coating composition Substances 0.000 claims description 4
239000013543 active substance Substances 0.000 abstract description 13
150000002148 esters Chemical class 0.000 abstract description 3
239000000470 constituent Substances 0.000 abstract 1
238000003892 spreading Methods 0.000 abstract 1
229920000642 polymer Polymers 0.000 description 41
SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 38
239000003826 tablet Substances 0.000 description 36
239000000725 suspension Substances 0.000 description 23
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 22
239000010410 layer Substances 0.000 description 20
239000007921 spray Substances 0.000 description 20
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 17
238000009472 formulation Methods 0.000 description 16
210000004051 gastric juice Anatomy 0.000 description 15
238000000151 deposition Methods 0.000 description 10
238000011068 loading method Methods 0.000 description 10
239000000902 placebo Substances 0.000 description 10
229940068196 placebo Drugs 0.000 description 10
239000000454 talc Substances 0.000 description 10
229910052623 talc Inorganic materials 0.000 description 10
235000012222 talc Nutrition 0.000 description 10
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 9
230000008021 deposition Effects 0.000 description 9
-1 dimethylaminobenzylmethacrylaminobenzylmethacrylaminobenzyl Chemical group 0.000 description 9
239000003814 drug Substances 0.000 description 9
238000001035 drying Methods 0.000 description 9
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 9
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 9
229920000053 polysorbate 80 Polymers 0.000 description 9
229940068968 polysorbate 80 Drugs 0.000 description 9
238000012545 processing Methods 0.000 description 9
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 8
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
239000007864 aqueous solution Substances 0.000 description 7
239000007900 aqueous suspension Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 7
230000000694 effects Effects 0.000 description 7
235000019333 sodium laurylsulphate Nutrition 0.000 description 7
235000019640 taste Nutrition 0.000 description 7
JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 6
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 6
239000006185 dispersion Substances 0.000 description 6
239000012875 nonionic emulsifier Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
125000001302 tertiary amino group Chemical group 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 5
230000006870 function Effects 0.000 description 5
239000011521 glass Substances 0.000 description 5
239000008187 granular material Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000002474 experimental method Methods 0.000 description 4
230000001788 irregular Effects 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
239000004570 mortar (masonry) Substances 0.000 description 4
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
239000002002 slurry Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 3
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 3
229920003149 Eudragit® E 100 Polymers 0.000 description 3
239000004809 Teflon Substances 0.000 description 3
229920006362 Teflon® Polymers 0.000 description 3
SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000009826 distribution Methods 0.000 description 3
239000000428 dust Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000002955 isolation Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 3
229960000907 methylthioninium chloride Drugs 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
239000008188 pellet Substances 0.000 description 3
230000035515 penetration Effects 0.000 description 3
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
229960004482 quinidine sulfate Drugs 0.000 description 3
230000005855 radiation Effects 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
239000004408 titanium dioxide Substances 0.000 description 3
239000001069 triethyl citrate Substances 0.000 description 3
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 3
235000013769 triethyl citrate Nutrition 0.000 description 3
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
230000003254 anti-foaming effect Effects 0.000 description 2
235000019658 bitter taste Nutrition 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
239000013078 crystal Substances 0.000 description 2
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
229960001259 diclofenac Drugs 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000013583 drug formulation Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000007888 film coating Substances 0.000 description 2
238000009501 film coating Methods 0.000 description 2
238000000227 grinding Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000003326 hypnotic agent Substances 0.000 description 2
230000000147 hypnotic effect Effects 0.000 description 2
229960001680 ibuprofen Drugs 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
229960000991 ketoprofen Drugs 0.000 description 2
230000000873 masking effect Effects 0.000 description 2
230000006996 mental state Effects 0.000 description 2
CXMXRPHRNRROMY-UHFFFAOYSA-N n-Decanedioic acid Natural products OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
229920002959 polymer blend Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229960003712 propranolol Drugs 0.000 description 2
NHARPDSAXCBDDR-UHFFFAOYSA-N propyl 2-methylprop-2-enoate Chemical compound CCCOC(=O)C(C)=C NHARPDSAXCBDDR-UHFFFAOYSA-N 0.000 description 2
239000011241 protective layer Substances 0.000 description 2
239000004172 quinoline yellow Substances 0.000 description 2
235000012752 quinoline yellow Nutrition 0.000 description 2
IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 2
229940051201 quinoline yellow Drugs 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
238000009997 thermal pre-treatment Methods 0.000 description 2
RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 2
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
DPBJAVGHACCNRL-UHFFFAOYSA-N 2-(dimethylamino)ethyl prop-2-enoate Chemical compound CN(C)CCOC(=O)C=C DPBJAVGHACCNRL-UHFFFAOYSA-N 0.000 description 1
NMBXBBSVGZNJCE-UHFFFAOYSA-N 2-(dimethylamino)propyl prop-2-enoate Chemical compound CN(C)C(C)COC(=O)C=C NMBXBBSVGZNJCE-UHFFFAOYSA-N 0.000 description 1
WWJCRUKUIQRCGP-UHFFFAOYSA-N 3-(dimethylamino)propyl 2-methylprop-2-enoate Chemical compound CN(C)CCCOC(=O)C(C)=C WWJCRUKUIQRCGP-UHFFFAOYSA-N 0.000 description 1
SQVIAVUSQAWMKL-UHFFFAOYSA-N 3-[2-(ethylamino)-1-hydroxyethyl]phenol Chemical compound CCNCC(O)C1=CC=CC(O)=C1 SQVIAVUSQAWMKL-UHFFFAOYSA-N 0.000 description 1
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
101100042016 Caenorhabditis elegans npp-20 gene Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000208202 Linaceae Species 0.000 description 1
235000004431 Linum usitatissimum Nutrition 0.000 description 1
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
239000006057 Non-nutritive feed additive Substances 0.000 description 1
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
BXBNSDRXIJBQSV-UHFFFAOYSA-N S(=O)(=O)(OC(C)=O)OCCCCCCCCCCCCCCCCCC.[Na] Chemical compound S(=O)(=O)(OC(C)=O)OCCCCCCCCCCCCCCCCCC.[Na] BXBNSDRXIJBQSV-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
239000000219 Sympatholytic Substances 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
FTIMEUKJNDNRFG-UHFFFAOYSA-N [dimethylamino(phenyl)methyl] prop-2-enoate Chemical compound C=CC(=O)OC(N(C)C)C1=CC=CC=C1 FTIMEUKJNDNRFG-UHFFFAOYSA-N 0.000 description 1
230000037374 absorbed through the skin Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
238000004026 adhesive bonding Methods 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229960004538 alprazolam Drugs 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 1
229960005174 ambroxol Drugs 0.000 description 1
150000001412 amines Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
239000000043 antiallergic agent Substances 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000000729 antidote Substances 0.000 description 1
229940075522 antidotes Drugs 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000002255 antigout agent Substances 0.000 description 1
229960002708 antigout preparations Drugs 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
230000001813 broncholytic effect Effects 0.000 description 1
CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
239000002302 calcium metabolism regulator Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
238000003490 calendering Methods 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
229960000623 carbamazepine Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000011258 core-shell material Substances 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
229940079919 digestives enzyme preparation Drugs 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
238000010410 dusting Methods 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000003172 expectorant agent Substances 0.000 description 1
230000003419 expectorant effect Effects 0.000 description 1
229940066493 expectorants Drugs 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
229960002428 fentanyl Drugs 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
231100001261 hazardous Toxicity 0.000 description 1
UFIYKNIUNRVRSI-UHFFFAOYSA-N hexadecyl octadecyl sulfate;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCCOS(=O)(=O)OCCCCCCCCCCCCCCCC UFIYKNIUNRVRSI-UHFFFAOYSA-N 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
239000005555 hypertensive agent Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
238000009413 insulation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
235000013980 iron oxide Nutrition 0.000 description 1
VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000003475 lamination Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000000155 melt Substances 0.000 description 1
238000010128 melt processing Methods 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
238000003801 milling Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
229960004127 naloxone Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
238000005453 pelletization Methods 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
238000009512 pharmaceutical packaging Methods 0.000 description 1
125000005498 phthalate group Chemical class 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000003672 processing method Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
238000010526 radical polymerization reaction Methods 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
229960002646 scopolamine Drugs 0.000 description 1
238000012216 screening Methods 0.000 description 1
150000003329 sebacic acid derivatives Chemical class 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000010129 solution processing Methods 0.000 description 1
230000002048 spasmolytic effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000003445 sucroses Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000000948 sympatholitic effect Effects 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
229940064707 sympathomimetics Drugs 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960002726 vincamine Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000012463 white pigment Substances 0.000 description 1
239000003357 wound healing promoting agent Substances 0.000 description 1
229940124629 β-receptor antagonist Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S524/00—Synthetic resins or natural rubbers -- part of the class 520 series
- Y10S524/904—Powder coating compositions

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Compositions Of Macromolecular Compounds (AREA)
Paints Or Removers (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SK79-2001A 1998-07-23 1999-07-02 Method for production of coating and excipient agent for oral or dermal dosage forms SK287838B6 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19833016		1998-07-23
DE19918435A DE19918435A1 (de)	1998-07-23	1999-04-23	Überzugs- und Bindemittel für orale oder dermale Arzneiformen
PCT/EP1999/004620 WO2000005307A1 (fr)	1998-07-23	1999-07-02	Agent servant d'enrobant et d'excipient pour formes medicamenteuses orales ou cutanees

Publications (2)

Publication Number	Publication Date
SK792001A3 SK792001A3 (en)	2002-01-07
SK287838B6 true SK287838B6 (sk)	2011-12-05

Family

ID=26047615

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK79-2001A SK287838B6 (sk)	1998-07-23	1999-07-02	Method for production of coating and excipient agent for oral or dermal dosage forms

Country Status (18)

Country	Link
US (2)	US6624210B1 (fr)
EP (1)	EP1098935B1 (fr)
JP (1)	JP4636687B2 (fr)
KR (2)	KR100663663B1 (fr)
CN (1)	CN1142212C (fr)
AT (1)	ATE230426T1 (fr)
AU (1)	AU4781599A (fr)
BR (1)	BR9912353B1 (fr)
CA (1)	CA2338750C (fr)
DE (2)	DE19918435A1 (fr)
ES (1)	ES2190226T3 (fr)
HK (1)	HK1041014B (fr)
IL (1)	IL140771A (fr)
MX (1)	MX217361B (fr)
PL (1)	PL199235B1 (fr)
SK (1)	SK287838B6 (fr)
TR (1)	TR200100196T2 (fr)
WO (1)	WO2000005307A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10220470A1 (de) *	2002-04-30	2003-11-20	Roehm Gmbh	ph-sensitives Polymer
PL202884B1 (pl) *	2000-02-10	2009-07-31	Bpsi Holdings	Nietoksyczna, jadalna, powłokotwórcza kompozycja proszkowa zabezpieczająca przed działaniem soku żołądkowego, sposób sporządzania wodnego układu dyspersyjnego oraz sposób powlekania substratów
DE10011447A1 (de)	2000-03-10	2001-09-20	Roehm Gmbh	Dispersion mit nichtionischem Emulgator
DE50103919D1 (de) *	2000-12-04	2004-11-04	Gruesner Uwe Emil Christian	Vorrichtung zur Beschichtung eines Gegenstands mit einem Wirkstoff und Verfahren zur Herstellung eines partiellen oder vollständigen Wirkstoffüberzuges auf und im Implantaten und Onplantaten sowie Verwendung dieses Verfahrens und durch dieses Verfahren hergestelltes Erzeugnis
DE10061704A1 (de) *	2000-12-12	2002-06-20	Hans Joerg Bauer	Verfahren und Vorrichtung zur Herstellung von biologischem Gewebe in einer Wachstumskammer
GB0102342D0 (en) *	2001-01-30	2001-03-14	Smithkline Beecham Plc	Pharmaceutical formulation
DE50107641D1 (de) *	2001-02-27	2005-11-10	Roehm Gmbh	Überzugs- und bindemittel für arzneimittelformulierungen mit verbesserter lagerstabilität
JP2002255807A (ja) *	2001-02-28	2002-09-11	Kobayashi Pharmaceut Co Ltd	抗菌剤
DE10239999A1 (de) *	2002-08-27	2004-03-04	Röhm GmbH & Co. KG	Granulat oder Pulver zur Herstellung von Überzugs- und Bindemitteln für Arzneiformen
DE10260920A1 (de) *	2002-12-20	2004-07-01	Röhm GmbH & Co. KG	Verfahren zur Herstellung von Arnzeiformen oder Nahrungsergänzungsmitteln mit pigmentierten Polymerüberzügen
DE10260919A1 (de) *	2002-12-20	2004-07-01	Röhm GmbH & Co. KG	Verfahren zur Herstellung von überzogenen Arzneiformen und Nahrungsergänzungsmitteln mit Konzentrationsgradienten im Überzug
DE10260921A1 (de) *	2002-12-20	2004-07-01	Röhm GmbH & Co. KG	Verfahren zum Überziehen von Substraten für pharmazeutische Anwendungen mit einem Gemisch aus zwei filmbildenden Überzugsmitteln
DE10304403A1 (de) *	2003-01-28	2004-08-05	Röhm GmbH & Co. KG	Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
DE10306604A1 (de) *	2003-02-18	2004-08-26	Goldschmidt Ag	Kosmetische Zubereitungen mit Wirkstoffen in Mikrokapseln
US8802139B2 (en)	2003-06-26	2014-08-12	Intellipharmaceutics Corp.	Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
AU2003288707B2 (en) *	2003-12-15	2007-08-02	Council Of Scientific & Industrial Research	Taste masked pharmaceutical composition comprising pH sensitive polymer
WO2005055987A1 (fr) *	2003-12-15	2005-06-23	Council Of Scientific & Industrial Research	Compositions pharmaceutiques au gout masque comportant une medicament amer et un polymere sensible au ph
US20050136114A1 (en) *	2003-12-19	2005-06-23	Council Of Scientific And Industrial Research	Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer
US8394409B2 (en)	2004-07-01	2013-03-12	Intellipharmaceutics Corp.	Controlled extended drug release technology
US10624858B2 (en) *	2004-08-23	2020-04-21	Intellipharmaceutics Corp	Controlled release composition using transition coating, and method of preparing same
US20060127479A1 (en) *	2004-10-08	2006-06-15	Natrajan Kumaraperumal	Solvent free taste masked pharmaceutical compositions
EP1845937A1 (fr) *	2004-12-10	2007-10-24	Of Scientific & Industrial Research Council	Composition pharmaceutique visant a ameliorer la sapidite de medicaments et procede de preparation de ladite composition
US8874082B2 (en) *	2005-05-25	2014-10-28	Qualcomm Incorporated	Apparatus and methods for protecting data on a wireless device
DE102005042039A1 (de) *	2005-09-02	2007-03-08	Basf Ag	Wässrige Polyvinylacetatdispersionen mit hoher Scherstabilität
US7811604B1 (en)	2005-11-14	2010-10-12	Barr Laboratories, Inc.	Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
US10064828B1 (en)	2005-12-23	2018-09-04	Intellipharmaceutics Corp.	Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US9561188B2 (en)	2006-04-03	2017-02-07	Intellipharmaceutics Corporation	Controlled release delivery device comprising an organosol coat
US10960077B2 (en)	2006-05-12	2021-03-30	Intellipharmaceutics Corp.	Abuse and alcohol resistant drug composition
WO2009016258A1 (fr)	2007-08-02	2009-02-05	Basf Se	Dispersion polymère aqueuse à base de n,n-diéthylaminoéthylméthacrylate, mode de production et utilisation correspondants
WO2009079555A2 (fr) *	2007-12-17	2009-06-25	Anna Love	Matière de remplissage pour tissus mous
JP5619131B2 (ja) *	2009-03-18	2014-11-05	エボニックレームゲゼルシャフトミットベシュレンクテルハフツングＥｖｏｎｉｋＲｏｅｈｍＧｍｂＨ	ポリマー混合物と賦形剤とを含むコーティングを使用するエタノールの影響に対する耐性を有する制御放出性医薬組成物
WO2011051155A2 (fr) *	2009-10-28	2011-05-05	Basf Se	Enrobages protecteurs stables pour formes pharmaceutiques
CN103189052A (zh)	2010-09-07	2013-07-03	巴斯夫欧洲公司	基于含氨基聚合物的共聚物作为基质粘合剂在制备含活性成分的颗粒和给药形式中的用途
US9795576B2 (en)	2010-09-27	2017-10-24	Basf Se	Protective coatings for acidic active ingredients
JP6012604B2 (ja)	2010-09-27	2016-10-25	ビーエーエスエフソシエタス・ヨーロピアＢａｓｆＳｅ	酸性有効成分のための保護コーティング
CA2814555C (fr) *	2010-10-13	2017-09-19	Evonik Roehm Gmbh	Procede pour la preparation d'un copolymere de (meth)acrylate contenant des groupes amino tertiaires par polymerisation radicalaire en solution
US8962064B2 (en)	2011-02-28	2015-02-24	Basf Se	Production of pulverulent coating compositions for stable protective coatings for pharmaceutical dosage forms
JP5937113B2 (ja)	2011-02-28	2016-06-22	ビーエーエスエフソシエタス・ヨーロピアＢａｓｆＳｅ	医薬剤形用の安定した保護被覆のための粉末被覆剤の製造
JP6027550B2 (ja)	2011-02-28	2016-11-16	ビーエーエスエフソシエタス・ヨーロピアＢａｓｆＳｅ	医薬剤形用の安定した保護被覆のための粉末被覆剤の製造
US8865250B2 (en)	2011-02-28	2014-10-21	Basf Se	Production of pulverulent coating compositions for stable protective coatings for pharmaceutical dosage forms
US9044734B2 (en)	2011-09-23	2015-06-02	Basf Se	Diesel oxidation catalyst with layered structure containing ceria composition as palladium support material for enhanced HC and CO gas conversion
EP2636403A1 (fr)	2012-03-09	2013-09-11	Basf Se	Fabrication de revêtements de protection pharmaceutiques ayant une bonne résistance en milieu neutre
US20130236505A1 (en)	2012-03-09	2013-09-12	Basf Se	Production Of Pharmaceutical Protective Coatings With Good Resistance In A Neutral Environment
US10668156B2 (en)	2012-06-22	2020-06-02	Basf Se	Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
EP2863953A1 (fr)	2012-06-22	2015-04-29	Basf Se	Dispersions solides renfermant des principes actifs à base de compolymères de diéthylaminoéthylméthacrylate
CN104812416A (zh)	2012-09-28	2015-07-29	赢创工业集团股份有限公司	制备水分散体的方法
FR3007290B1 (fr) *	2013-06-25	2015-06-26	Expressions Aromatiques	Procede de fabrication de granules contenant un principe actif, a dluo et charge en principe actif optimisees
US10744070B2 (en)	2015-06-19	2020-08-18	University Of Southern California	Enteral fast access tract platform system
US10631564B2 (en)	2015-06-19	2020-04-28	University Of Southern California	Enterically coated microparticle compositions and methods for modified nutrient delivery
EP4061863B1 (fr) *	2019-11-21	2025-07-16	Dow Global Technologies LLC	Polymère multi-étapes
CN111410714A (zh) *	2020-05-16	2020-07-14	连云港万泰医药辅料技术有限公司	一种胃溶型包衣材料聚丙烯酸树脂ⅳ的制备方法
US20220175812A1 (en)	2020-12-03	2022-06-09	Battelle Memorial Institute	Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
AU2022253899A1 (en)	2021-04-07	2023-10-26	Battelle Memorial Institute	Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (fr)	2023-09-29	2025-04-03	Battelle Memorial Institute	Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
US12441996B2 (en)	2023-12-08	2025-10-14	Battelle Memorial Institute	Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3049179A1 (de) *	1975-03-20	1982-07-29	Röhm GmbH, 6100 Darmstadt	Bindemittel fuer arzneimittelueberzuege.
DE2543542C2 (de) *	1975-09-30	1986-10-02	Röhm GmbH, 6100 Darmstadt	Verfahren zur Herstellung eines Plastisols
DE3421860C2 (de) *	1984-06-13	1994-09-15	Roehm Gmbh	Verfahren zum Überziehen von Arzneiformen
DE3581428D1 (de) *	1984-06-13	1991-02-28	Roehm Gmbh	Verfahren zum ueberziehen von arzneiformen.
DE3438291A1 (de) *	1984-10-19	1986-04-24	Röhm GmbH, 6100 Darmstadt	Verfahren zur herstellung einer waessrigen ueberzugsmitteldispersion und ihre verwendung zum ueberziehen von arzneimitteln
US5025004A (en) *	1988-06-13	1991-06-18	Eastman Kodak Company	Water-dispersible polymeric compositions
US5292522A (en) *	1989-06-20	1994-03-08	Rohm Gmbh	Aqueous film coating agent for solid medicaments
DE4310012A1 (de) *	1993-03-27	1994-09-29	Roehm Gmbh	Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
DE29502547U1 (de) *	1995-02-16	1995-03-30	Röhm GmbH, 64293 Darmstadt	Thermoplastisches Überzugs- und Bindemittel für Arzneiformen
US6391338B1 (en) *	1995-09-07	2002-05-21	Biovail Technologies Ltd.	System for rendering substantially non-dissoluble bio-affecting agents bio-available
WO1997039740A1 (fr) *	1996-04-22	1997-10-30	Toyama Chemical Co., Ltd.	Timbre contenant des derives du 1,2-ethanediol ou leurs sels
JP4227677B2 (ja) *	1996-12-10	2009-02-18	杏林製薬株式会社	被膜形成性抗真菌剤組成物
DE19653606A1 (de) *	1996-12-20	1998-06-25	Roehm Gmbh	Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher
JP3962963B2 (ja) *	1997-06-09	2007-08-22	荒川化学工業株式会社	四級アンモニウム塩基を有するポリマーおよびその製造方法
JP2001518490A (ja) *	1997-10-03	2001-10-16	エランコーポレーシヨンピーエルシー	味遮蔽された製剤

1999
- 1999-04-23 DE DE19918435A patent/DE19918435A1/de not_active Withdrawn
- 1999-07-02 KR KR1020067014125A patent/KR100663663B1/ko not_active Expired - Fee Related
- 1999-07-02 AT AT99931245T patent/ATE230426T1/de active
- 1999-07-02 MX MXPA01000793 patent/MX217361B/es not_active IP Right Cessation
- 1999-07-02 CN CNB998079669A patent/CN1142212C/zh not_active Expired - Fee Related
- 1999-07-02 ES ES99931245T patent/ES2190226T3/es not_active Expired - Lifetime
- 1999-07-02 JP JP2000561259A patent/JP4636687B2/ja not_active Expired - Fee Related
- 1999-07-02 HK HK02100486.9A patent/HK1041014B/zh not_active IP Right Cessation
- 1999-07-02 BR BRPI9912353-3A patent/BR9912353B1/pt not_active IP Right Cessation
- 1999-07-02 AU AU47815/99A patent/AU4781599A/en not_active Abandoned
- 1999-07-02 PL PL345581A patent/PL199235B1/pl unknown
- 1999-07-02 WO PCT/EP1999/004620 patent/WO2000005307A1/fr not_active Ceased
- 1999-07-02 US US09/764,993 patent/US6624210B1/en not_active Expired - Lifetime
- 1999-07-02 DE DE59903917T patent/DE59903917D1/de not_active Expired - Lifetime
- 1999-07-02 KR KR1020017001032A patent/KR100646114B1/ko not_active Expired - Fee Related
- 1999-07-02 SK SK79-2001A patent/SK287838B6/sk not_active IP Right Cessation
- 1999-07-02 CA CA002338750A patent/CA2338750C/fr not_active Expired - Fee Related
- 1999-07-02 TR TR2001/00196T patent/TR200100196T2/xx unknown
- 1999-07-02 EP EP99931245A patent/EP1098935B1/fr not_active Expired - Lifetime
- 1999-07-02 IL IL14077199A patent/IL140771A/xx not_active IP Right Cessation
2003
- 2003-06-18 US US10/463,539 patent/US6846891B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
PL199235B1 (pl)	2008-08-29
WO2000005307A1 (fr)	2000-02-03
SK792001A3 (en)	2002-01-07
US6624210B1 (en)	2003-09-23
US20030220413A1 (en)	2003-11-27
MXPA01000793A (es)	2002-04-08
KR20010079560A (ko)	2001-08-22
DE19918435A1 (de)	2000-01-27
AU4781599A (en)	2000-02-14
BR9912353B1 (pt)	2012-01-24
IL140771A0 (en)	2002-02-10
KR100663663B1 (ko)	2007-01-03
US6846891B2 (en)	2005-01-25
HK1041014B (zh)	2004-10-08
ES2190226T3 (es)	2003-07-16
DE59903917D1 (de)	2003-02-06
MX217361B (es)	2003-11-04
PL345581A1 (en)	2001-12-17
HK1041014A1 (en)	2002-06-28
CA2338750A1 (fr)	2000-02-03
CN1142212C (zh)	2004-03-17
JP4636687B2 (ja)	2011-02-23
CN1307613A (zh)	2001-08-08
KR20060092288A (ko)	2006-08-22
CA2338750C (fr)	2009-12-08
ATE230426T1 (de)	2003-01-15
EP1098935B1 (fr)	2003-01-02
IL140771A (en)	2005-06-19
BR9912353A (pt)	2001-04-17
TR200100196T2 (tr)	2001-06-21
EP1098935A1 (fr)	2001-05-16
KR100646114B1 (ko)	2006-11-17
JP2002521393A (ja)	2002-07-16

Publication	Publication Date	Title
SK287838B6 (sk)	2011-12-05	Method for production of coating and excipient agent for oral or dermal dosage forms
KR100510356B1 (ko)	2005-08-24	저장 안정성이 개선된 피복제 및 결합제를 포함하는 약제학적 제형 및 이의 제조방법
CA2435729C (fr)	2005-12-13	Nouvelle pellicule
US6878387B1 (en)	2005-04-12	Coated medicament forms with controlled active substance release
US6656507B2 (en)	2003-12-02	Aqueous dispersion suitable for the production of coatings and binders for solid oral drugs
Skalsky et al.	2008	Chemistry and application properties of polymethacrylate systems

Legal Events

Date	Code	Title	Description
2010-06-07	PC4A	Assignment and transfer of rights	Owner name: ROEHM GMBH, DARMSTADT, DE Free format text: FORMER OWNER: ROEHM GMBH & CO. KG, DARMSTADT, DE Effective date: 20100413
2010-06-07	TC4A	Change of owner's name	Owner name: EVONIK ROEHM GMBH, DARMSTADT, DE Effective date: 20100413
2019-04-02	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20180702

Date

Code

Title

Description

2010-06-07

PC4A

Assignment and transfer of rights

Owner name: ROEHM GMBH, DARMSTADT, DE

Free format text: FORMER OWNER: ROEHM GMBH & CO. KG, DARMSTADT, DE

Effective date: 20100413

2010-06-07

TC4A

Change of owner's name

Owner name: EVONIK ROEHM GMBH, DARMSTADT, DE